Treatment of AML in biological subgroups.

about

Gene expression profiling in MDS and AML: potential and future avenues.

P2860

Q37858877-5F168E8C-85CF-41CF-88A6-4EB496C20FFA

P2860

Treatment of AML in biological subgroups.

Item

http://www.wikidata.org/entity/Q36308975

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Treatment of AML in biological subgroups.

@ast

Treatment of AML in biological subgroups.

@en

type

Item

label

Treatment of AML in biological subgroups.

@ast

Treatment of AML in biological subgroups.

@en

prefLabel

Treatment of AML in biological subgroups.

@ast

Treatment of AML in biological subgroups.

@en

P1476

Treatment of AML in biological subgroups.

@en

P2093

Achim Heinecke

http://www.w3.org/2001/XMLSchema#string

Albrecht Reichle

http://www.w3.org/2001/XMLSchema#string

Bernhard Woermann

http://www.w3.org/2001/XMLSchema#string

German Acute Myeloid Leukemia Cooperative Group (AMLCG)

http://www.w3.org/2001/XMLSchema#string

Hubert L Serve

http://www.w3.org/2001/XMLSchema#string

Joelle Tchinda

http://www.w3.org/2001/XMLSchema#string

Maria-Cristina Sauerland

http://www.w3.org/2001/XMLSchema#string

Peter Staib

http://www.w3.org/2001/XMLSchema#string

Thomas Buechner

http://www.w3.org/2001/XMLSchema#string

Wolf-Dieter Ludwig

http://www.w3.org/2001/XMLSchema#string

P2860

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.

The treatment of acute myeloid leukaemia preceded by the myelodysplastic syndrome.

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia.

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.

P304

281-285

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10245330512331390212

http://www.w3.org/2001/XMLSchema#string

P478

10 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7490911

http://www.w3.org/2001/XMLSchema#string

P698

16276628

http://www.w3.org/2001/XMLSchema#string

Treatment of AML in biological subgroups.

about

P2860

P2860

Treatment of AML in biological subgroups.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698